Skip to main content
Oxford Biomedica PLC logo

Oxford Biomedica PLC - Investor Relations & Filings

Listed IPO Apr 2001
Ticker · OXB ISIN · GB00BDFBVT43 LEI · 213800S1GVQNXQ15K851 IL Manufacturing
Open in API
Filings indexed 927 across all filing types
Latest filing 2026-01-19 Regulatory Filings
Country GB United Kingdom
Listing IL OXB · 7 venues

Key figures FY2025

Period ended 2025-12-31 · GBP
Headline annual figures for Oxford Biomedica PLC, fiscal year 2025, reported in GBP, with the source filing for each figure.
Total Revenues GBP 168.74M per the Annual Report (ESEF) filed 2026-03-30
Net Income GBP -30.64M per the Annual Report (ESEF) filed 2026-03-30
Total Assets GBP 325.72M per the Annual Report (ESEF) filed 2026-03-30
Total Equity GBP 91.35M per the Annual Report (ESEF) filed 2026-03-30
Cash from Ops GBP 507.00k per the Annual Report (ESEF) filed 2026-03-30

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About Oxford Biomedica PLC

https://www.oxb.com/

Oxford Biomedica (OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. A pioneer in the field, the company has extensive experience in viral vectors, the enabling technology for many advanced therapies. OXB provides end-to-end services to pharmaceutical and biotechnology partners, supporting programs from preclinical development through to commercial launch. Its core expertise includes the development and GMP manufacturing of various vector types, including lentivirus, adeno-associated virus (AAV), and adenovirus. The company offers proprietary technologies like its LentiVector™ platform, the first commercially approved lentiviral system, and its inAAVate™ platform for AAV, in addition to tech-transfer capabilities.

Recent filings

Filing Released Lang Actions
Rule 2.9 Announcement
Regulatory Filings Classification · 95% confidence The document is a 'Rule 2.9 Announcement' issued by Oxford Biomedica plc in accordance with the UK City Code on Takeovers and Mergers. This rule requires a company to disclose its total number of issued shares and voting rights during an offer period. While it relates to M&A activity (takeover code), it is specifically a regulatory disclosure regarding capital structure and voting rights required by the Takeover Panel, rather than a merger proposal or takeover bid document itself. Therefore, it is best classified as a Regulatory Filing (RNS).
2026-01-19 English
Response to press speculation
M&A Activity Classification · 100% confidence The document is an official announcement from Oxford Biomedica PLC regarding an unsolicited takeover approach from EQT. It explicitly references 'Rule 2.4 of the City Code on Takeovers and Mergers' and discusses potential acquisition proposals. This falls squarely under M&A activity, specifically the announcement of a potential takeover bid or merger proposal.
2026-01-14 English
Block Listing Return
Regulatory Filings Classification · 98% confidence The document is a 'Block Listing Six Monthly Return' filed by Oxford Biomedica PLC. It details the issuance of securities under various employee share option and incentive schemes over a six-month period. This type of filing is a standard regulatory requirement for companies listed on the London Stock Exchange to report changes in their capital structure related to employee share schemes. It falls under the 'Share Issue/Capital Change' category as it reports the allotment of new shares.
2026-01-02 English
Total Voting Rights
Regulatory Filings Classification · 100% confidence The document is a standard regulatory announcement regarding 'Total Voting Rights' issued by Oxford Biomedica PLC in accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1R. It provides the total number of voting rights and issued share capital to assist shareholders with regulatory notification requirements. As this is a general regulatory announcement that does not fit into specific categories like share issuance or director dealings, it is classified as a Regulatory Filing (RNS).
2026-01-02 English
PDMR Dealing
Director's Dealing Classification · 100% confidence The document is a formal notification of 'PDMR Dealing' (Person Discharging Managerial Responsibility), detailing the exercise of share options and subsequent sale of shares by company executives. This falls directly under the definition of 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2025-12-08 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a standard 'Total Voting Rights' announcement issued by Oxford Biomedica PLC in accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1R. This type of filing provides the total number of voting rights and issued share capital to assist shareholders in calculating their notification obligations. While it relates to share capital, it is a regulatory disclosure requirement rather than a transaction in own shares (POS) or a major shareholding notification (MRQ). Since it is a standard regulatory announcement provided via RNS, it falls under the 'Regulatory Filings' category.
2025-12-01 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.